Experience with irinotecan for the treatment of malignant glioma.
Malignant glioma is the most commonly occurring primary malignant brain tumor. It is difficult to treat and is usually associated with an inexorable, rapidly fatal clinical course. Chemotherapy, radiotherapy, and surgical excision are core components in the management of malignant glioma. However, chemotherapy, even with the most active regimens currently available, achieves only modest improvement in overall survival. Novel agents and new approaches to therapy are required to improve clinical outcomes. Irinotecan, a first-line treatment for metastatic colorectal cancer and an agent with high activity against solid tumors of the gastrointestinal tract, is an inhibitor of topoisomerase I, a critical enzyme needed for DNA transcription. Irinotecan crosses the blood-brain barrier and, in preclinical investigations, has demonstrated cytotoxic activity against central nervous system tumor xenografts. Its antitumor activity has also been demonstrated against glioblastoma cells with multidrug resistance. Studies in adult and pediatric patients with recurrent, intractable malignant glioma have evaluated irinotecan as monotherapy and in combination with other agents, including temozolomide, carmustine, thalidomide, and bevacizumab. Studies of irinotecan in combination with other medications, particularly temozolomide and bevacizumab, have yielded promising results. Irinotecan monotherapy has demonstrated efficacy; however, its efficacy appears to be enhanced when used in combination with other chemotherapeutic agents. When administered concurrently with enzyme-inducing antiepileptic drugs, the dosage must be increased to compensate for enhanced cytochrome CY3A4/5 enzyme activity. Toxicities associated with irinotecan have been manageable; the most important dose-limiting toxicities are neutropenia and diarrhea. Irinotecan-based chemotherapy of malignant glioma merits further study.
Vredenburgh
James J
JJ
The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC 27710, USA. vrede001@mc.duke.edu
Desjardins
Annick
A
Reardon
David A
DA
Friedman
Henry S
HS
D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D000077146:Irinotecan; D059004:Topoisomerase I Inhibitors
D000972:Antineoplastic Agents, Phytogenic; D059004:Topoisomerase I Inhibitors; D000077146:Irinotecan; D002166:Camptothecin
Eur J Cancer. 2006 Mar;42(5):582-8
16427778
Cancer Res. 1991 Aug 15;51(16):4187-91
1651156
Biol Pharm Bull. 2007 Aug;30(8):1400-6
17666793
J Neurooncol. 2002 Jan;56(2):183-8
11995820
Cancer Res. 2000 Dec 15;60(24):6921-6
11156391
Invest New Drugs. 2000 Aug;18(3):275-80
10958598
Clin Cancer Res. 2006 Jan 15;12(2):328-31
16428468
Am J Clin Oncol. 2002 Apr;25(2):204-8
11943904
Cancer. 2003 May 1;97(9 Suppl):2363-73
12712458
Clin Cancer Res. 2007 Feb 15;13(4):1253-9
17317837
J Clin Oncol. 2004 Dec 1;22(23):4779-86
15570079
Ann Neurol. 1998 Oct;44(4):691-5
9778271
J Clin Oncol. 2007 Oct 20;25(30):4722-9
17947719
Cancer. 2008 Mar 1;112(5):1139-46
18246536
Cancer Treat Rev. 2006 Nov;32(7):491-503
16959432
Cancer Chemother Pharmacol. 1997;39(5):417-23
9054955
Neuro Oncol. 2004 Apr;6(2):145-53
15134629
Br J Cancer. 2006 Jul 17;95(2):131-8
16835584
Lancet Neurol. 2007 May;6(5):421-30
17434097
Cancer. 2003 May 1;97(9 Suppl):2381-6
12712460
Cancer. 2004 Nov 15;101(10):2293-9
15476282
Am J Clin Oncol. 2004 Feb;27(1):33-8
14758131
Cancer Lett. 2006 Jan 8;231(1):74-86
16356833
N Engl J Med. 2000 Nov 9;343(19):1350-4
11070098
Neuro Oncol. 2004 Apr;6(2):134-44
15134628
Clin Cancer Res. 2002 Jul;8(7):2202-9
12114421
Semin Oncol. 2003 Dec;30(6 Suppl 19):15-8
14765379
Cancer Treat Rev. 1994 Jan;20(1):73-96
8293429
Neuro Oncol. 2002 Apr;4(2):102-8
11916501
Clin Cancer Res. 2000 May;6(5):2012-20
10815927
J Clin Oncol. 2007 Oct 20;25(30):4714-21
17947718
N Engl J Med. 2005 Mar 10;352(10):997-1003
15758010
J Clin Oncol. 1999 May;17(5):1516-25
10334539
Ann Oncol. 2003 Apr;14(4):603-14
12649109
Cancer Chemother Pharmacol. 1997;39(3):187-91
8996518
Br J Clin Pharmacol. 2006 Mar;61(3):246-55
16487217
Cancer. 2004 Apr 15;100(8):1750-7
15073866
Int J Cancer. 1997 Nov 27;73(5):707-14
9398050
Cochrane Database Syst Rev. 2002;(4):CD003913
12519620
Drug Metab Dispos. 1997 Oct;25(10):1157-64
9321519
J Nucl Med. 2005 Jun;46(6):945-52
15937304
Br J Cancer. 1996 Aug;74(4):537-45
8761367
Ann Oncol. 2002 Dec;13(12):1841-51
12453851
Neuro Oncol. 2004 Jan;6(1):21-7
14769136
Neuro Oncol. 2006 Apr;8(2):189-93
16533878
Cancer Chemother Pharmacol. 1998;41(6):464-8
9554590
Oncology (Williston Park). 2002 Aug;16(8 Suppl 7):33-40
12199631
Neuro Oncol. 2004 Jan;6(1):44-54
14769140
Cancer Res. 1996 Feb 15;56(4):783-8
8631014
Oncologist. 2006 Feb;11(2):152-64
16476836
Cancer Chemother Pharmacol. 1998;41(6):485-90
9554593
Clin Cancer Res. 2003 Aug 1;9(8):2940-9
12912940
Cancer. 2005 Jan 15;103(2):329-38
15558802
Neuro Oncol. 2008 Apr;10(2):216-22
18314417
J Clin Oncol. 2007 Aug 1;25(22):3357-61
17664483
Clin Adv Hematol Oncol. 2005 Nov;3(11):843-4
16491625
Pediatr Blood Cancer. 2007 Apr;48(4):403-7
16609952
Lancet. 2002 Mar 23;359(9311):1011-8
11937180
Indian J Exp Biol. 2005 Apr;43(4):313-23
15875714
Ann Oncol. 1996 Feb;7(2):205-7
8777179
Cancer Res. 1998 Mar 1;58(5):1068-73
9500473
Neurology. 2004 Oct 12;63(7):1281-4
15477552
Hematol Oncol Clin North Am. 2004 Oct;18(5):1161-81, x
15474340
J Clin Oncol. 2004 Apr 15;22(8):1382-8
15007088
Cancer. 2003 May 1;97(9 Suppl):2352-8
12712456
J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):250-2
7876865
Nat Med. 1998 Nov;4(11):1334-6
9809561
Semin Oncol. 2004 Oct;31(5):635-44
15497116
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
Semin Oncol. 2003 Dec;30(6 Suppl 19):4-9
14765377